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Autoimmune bullous dermatoses (AIBD) are characterized by circulating autoantibodies
that are either directed against epidermal antigens or deposited as immune complexes
in the basement membrane zone (BMZ). The complement system (CS) can be activated
by autoantibodies, thereby triggering activation of specific complement pathways. Local
complement activation induces a pathogenic inflammatory response that eventually
results in the formation of a sub- or intraepidermal blister. Deposition of complement
components is routinely used as a diagnostic marker for AIBD. Knowledge from different
animal models mimicking AIBD and deposition of complement components in human
skin biopsies provides more insight into the role of complement in the pathogenesis
of the different AIBD. This review outlines the role of the CS in several AIBD including
bullous pemphigoid, epidermolysis bullosa acquisita, mucous membrane pemphigoid
(MMP), pemphigus, linear IgA-disease, and dermatitis herpetiformis. We also discuss
potential therapeutic approaches targeting key complement components, pathways and
pathogenic complement-mediated events.
Keywords: complement, auto-immune bullous dermatosis, bullous pemphigod, epidermolysis bullosa acquisita,
mucus membrane pemphigoid, pemphigus, linear IgA bullous dermatoses, dermatitis herpetiformis
INTRODUCTION
The development of autoimmune bullous dermatoses (AIBD) is a complex interaction between
multiple parts of the innate and adaptive immune system. Bullous pemphigoid (BP) is the most
frequently encountered AIBD with an annual incidence estimated between 2.4 and 21.7 new cases
per million population in different populations worldwide (1). In AIBD, autoantibodies are either
directed against epidermal antigens or deposited as immune complexes in the basement membrane
zone (BMZ). Besides deposition of immunoglobulins as part of the adaptive immune system,
complement components can be found as part of the innate immune system. Secondary tissue
injury and blistering can be initiated by complement-dependent and complement-independent
mechanisms. Local complement activation triggers the release of cytokines and chemokines that
results in the recruitment of inflammatory cells, including neutrophils and eosinophils. This
pathogenic inflammatory response eventually results in the formation of sub- or intra-epidermal
blisters that will reveal its unique clinical features of the specific disease.
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The complement system (CS) is an important arm of the
innate immune system. It functions as a defense system against
pathogens and plays a major role in tissue homeostasis. The
CS has three distinct activation routes: the classical pathway
(CP), the alternative pathway (AP), and the lectin pathway (LP)
(Figure 1). Activation and regulation of the complement system
has been extensively outlined before by our group and therefore
we refer to our previous publication by Giang et al. for a more
detailed description (2).
BULLOUS PEMPHIGOID
Bullous pemphigoid (BP) is an AIBD characterized by
autoantibodies against BP180 and/or BP230. Most antibodies
in BP are directed against the NC16A domain of BP180,
which is a major non-collagenous extracellular antigenic site.
Clinically, patients present with tense pruritic dome-shaped,
fluid-filled blisters measuring up to several centimeters in
diameter. Histology reveals a subepidermal blister that is most
often accompanied by an infiltrate of lymphocytes, eosinophils,
neutrophils, mast cells, andmonocytes/macrophages. Deposition
of immunoglobulins and complement factor C3c are routinely
used for diagnostic purposes (Figure 2). In addition, deposition
of other complement factors of different complement pathways
has been demonstrated by direct immunofluorescence
(DIF) and immunoperoxidase staining on formalin-fixed
paraffin-embedded tissue (3–10). Besides the diagnostic use
of complement factors, mouse models have demonstrated an
important role for complement in the pathogenesis of BP. In
mice, Liu et al. passively transferred a rabbit-antibody against
murine BP180NC14A, a homolog of human BP180NC16A.
These mice developed a subepidermal blistering disease with
a phenotype closely mimicking human BP. Using this model,
serum complement depletion by cobra venom factor or C5-
deficiency protected against the development of BP. Also,
transfer of F(ab
′
)2-fragments derived from the anti-murine
BP180 antibody failed to induce a BP phenotype (11). These
findings indicate a crucial role for the IgG-Fc portion and
likely the CP, since the FC tail bears the C1q binding region.
In line with these findings, C4-KO mice as well as wildtype
mice treated with anti-mC1q were resistant to develop BP.
Besides a role for the CP, FB-deficient mice developed delayed
and less intense blisters, indicating involvement of the AP.
It is likely both the CP and AP act in concert when the
amplification loop is activated upon CP activation (12, 13).
So far, no role has been attributed to activation of the LP. It
is questionable whether the previously cited findings can be
translated into clinical practice, since BP180NC14a is poorly
preserved in mice. For this reasons, humanized mice models
were developed replacing mouse BP180NC14A by human
Abbreviations: AP, alternative pathway; AIBD, autoimmune bullous dermatoses;
BMZ, basement membrane zone; BP, bullous pemphigoid; C5aR1, C5a receptor
1; C5aR2, C5a receptor 2; CP, classical pathway; CS, complement system; DH,
dermatitis herpetiformis; DIF, direct immunofluorescence; KO, knock-out; LAD,
Linear IgA disease; LP, lectin pathway; MAC, membrane attack complex; MBL,
mannan binding lectin; MMP, mucous membrane pemphigoid.
BP180NC16A and introducing the human COL17 cDNA
transgene into Col17-null mice (14). Importantly, Liu et al. also
showed protection against BP in their humanized BP-model
after complement depletion with cobra venom factor (15). Also,
transfer of humanized IgG1 mutated at the C1q binding site
has shown lower pathogenicity in COL17-humanized neonatal
mice compared to unmutated humanized IgG1 (16). Although
these experiments confirm the complement-dependent blister
formation in BP, evidence emerges that also complement-
independent mechanisms exist. Karsten et al. have recently
demonstrated that the extent of skin lesions decreased with only
50% when C5-deficient mice were injected with anti-COL17
IgG in a humanized mouse model (17). This is in contrast
with the previously cited findings in the non-humanized
BP-model that showed full protection (11). The differences
might be explained by the use of the humanized model by
Karsten et al. or the existence of complement-independent
mechanisms. Natsuga et al. have demonstrated that rabbit
auto-antibodies specifically against the R7 domain within
human NC16A induced subepidermal blister formation in
COL17-humanized neonatal mice. It was found that the auto-
antibody after immunoadsorption against R7, or decoying
of R7 with BSA, significantly reduced skin fragility, despite
ongoing complement activation. Moreover, F(ab
′
)2 fragments
of anti-BP180 IgG antibodies from BP patients or rabbit IgG
against humanized NC16A induced (in part) skin fragility in
neonatal humanized mice (18). Lastly, Ujiie et al. found that
passive transfer of human BP auto-antibodies induced blister
formation in neonatal C3-deficient COL17 humanized mice
(19). Altogether, these studies indicate that it is highly likely
that also complement independent mechanisms play a role in
the pathogenesis of BP. One hypothesis is the direct pathogenic
effect of auto-antibodies against NC16A via macropinocytic
internalization, ubiquitination and degradation of BP180 leading
to impairment of hemidesmosome formation (19, 20). In
vitro studies indeed demonstrated direct pathogenic effects of
auto-antibodies and F(ab′)2 fragments leading to depletion
of BP180 in cultured keratinocytes (18, 19, 21). Although
complement-independent mechanisms are likely to exist, the
contradictory results between different studies could also be
explained by the differences in target epitopes on COL17 in the
models used, antibody concentration, antibody affinity, or the
clonality of antibodies in each experiment (19). Importantly,
conflicting results are observed between the humanized and
non-humanized models and could (in part) be explained by
the lower murine complement fixating and activating capacities
of the transferred human auto-antibodies compared to mouse
and/or rabbit antibodies (22).
Liu et al. further characterized complement in BP and found
that neutrophil depletion protected against the development of
BP in wildtype mice, while injection of C5a or IL-8 in C5-KO
mice regained susceptibility for BP (23). Moreover, absence of
C5aR1-expression on mast cells demonstrated similar protection
against BP development, despite complement activation and the
presence of neutrophils. It was found that in the BPmousemodel,
extensive mast cell degranulation occurs that precedes the influx
of neutrophil infiltration and subepidermal blister formation.
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FIGURE 1 | Schematic overview of the complement system. Figure adapted from Giang et al. (2).
These findings reveal that complement-dependent neutrophil
recruitment in BP acts, at least in part, via C5aR1-induced mast
cell degranulation (12, 24). Recently, this hypothesis was further
investigated by Karsten et al. who confirmed the protection
of C5aR1-KO mice against BP, whereas C5aR2-KO animals
were more susceptible for disease development. As a proof of
principle, prophylactic treatment with a C5aR1-inhibitor PMX53
in mice also led to reduced disease activity (17). Altogether, these
results indicate an important role for C5a-C5aR1-axis activation
in the development of BP and could be an interesting target
for intervention.
Although previous pre-clinical studies are encouraging, these
experiments were all performed in mice which makes it difficult
to translate these data to humans. However, Romeijn et al.
showed in a large patient study comprising 300 patients with
BP, that complement C3c was deposited in the majority of
(peri)lesional skin biopsies. More interestingly, the extent of
deposition was correlated with clinical and serological disease
activity, strengthening the crucial role of complement in this
disease (25). Besides the deposition of complement in the skin,
Chiorean et al. recently found that functional complement-
activation capacity of autoantibodies ex-vivo in BP also correlates
with severity of skin disease and autoantibody titers (26).
MUCOUS MEMBRANE PEMPHIGOID
Mucous membrane pemphigoid (MMP) is an AIBD. The disease
represents a spectrum, which affects both skin and mucosa,
especially the oral and ocular mucous membranes. Cutaneous
lesions manifest as tense blisters that, when ruptured, heal
slowly and usually result in scarring. Histopathology reveals a
subepidermal blister and a lymphocytic infiltrate in the upper
dermis with eosinophils and sometimes neutrophils. DIF shows
IgG- and C3c-deposition along the BMZ, but also IgA-, IgM-,
and fibrin-deposition can be found (27, 28). Various autoantigens
have been found in MMP including BP180 (BPAG2), BP230
(BPAG1), laminin 332, α6/β4 integrin, and laminin 6 (29). Early
DIF studies have found deposition of C3, C1q, C4, FB, and
properdin along the BMZ (28).
Experimental models that passively transferred rabbit anti-
laminin 5 (laminin 332) produced subepidermal blisters with
the same clinical, histologic, and immunopathologic features
of MMP. However, blistering could not be prevented in C5-
deficient mice, indicating that the terminal complement pathway
is not involved in blister formation in this experimental model
of MMP (30). Also, mice injected with F(ab′)2-fragments instead
of intact IgG, developed subepidermal blistering and a clinical
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FIGURE 2 | A case of bullous pemphigoid. Histology shows a subepidermal
blister (A) accompanied by specific linear C3c deposition along the BMZ
visualized by direct immunofluorescence (B). Figure (in part) adapted from
Giang et al. (2).
MMP phenotype comparable to wildtype mice. These results
strongly argue against a complement-dependent mechanism of
blister formation in MMP (31). In a recent study by Heppe
et al. a mouse MMP model was developed by passive transfer of
rabbit anti-laminin 332 specifically against 2 immunodominant
regions of LAMα3 in adult mice. The model reflects major
clinical and immunopathological characteristics of the human
disease. In contrast to the previously described model by
Lazarova et al. mice in this model also developed conjunctival
lesions and therefore might reflect the clinical situation more
accurately. Importantly, clear differences were observed between
the two models concerning complement activation. In contrast
to Lazarova et al. development of MMP in the model of Heppe
et al. was complement-dependent. Mice deficient in C5aR1 or
FCqR showed reduced or no signs of MMP. Differences could
be explained by the use of IgG against LAMa3 and the use of
adult mice by Heppe et al. compared to the use of IgG against all
subunits of human laminin 332 and neonatal mice by Lazarova
et al. (29, 31).
EPIDERMOLYSIS BULLOSA ACQUISITA
Epidermolysis bullosa acquisita is a rare chronic subepidermal
AIBD affecting skin and/or mucous membranes. It usually
manifests in adults with lesions resembling dystrophic
epidermolysis bullosa and is diagnosed after exclusion of all other
acquired bullous dermatoses. The disease is characterized by
tissue-bound and circulating IgG-autoantibodies against type VII
collagen as well as linear u-serrated deposition of complement
components along the BMZ (32, 33). In the mechanobullous
variant, light microscopy reveals a subepidermal blister, a cell-
free subepidermal vesicle, and usually no dermal inflammation.
The inflammatory variant frequently resembles histological
features of BP.
Experimental mouse models have demonstrated a
subepidermal blistering phenotype upon passive administration
of rabbit-anti-mouse collagen VII. Moreover, passive transfer
of human epidermolysis bullosa acquisita-autoantibodies
caused subepidermal blistering and induction of epidermolysis
bullosa acquisita skin lesions in mice, proving the pathogenicity
of these autoantibodies (34). Similar results were found in
an active model of epidermolysis bullosa acquisita in which
mice developed subepidermal blisters after immunization with
collagen VII (35). These mice showed deposition of IgG as well as
complement C3 along the BMZ. Comparable to BP, the findings
in experimental epidermolysis bullosa acquisita models were also
C5 and rabbit IgG-Fc portion dependent and suggests a role for
the CP via C1q-FC-receptor binding (34, 36, 37). However, C1q-
KO and MBL-KO mice were still susceptible for epidermolysis
bullosa acquisita development, comparable to wildtype mice. To
further unravel the complement pathways involved, Mihai et al.
demonstrated that FB-deficient or wildtype-mice treated with
anti-FB developed a delayed and less severe blistering disease
compared to wildtype-mice (37, 38). These results attribute
an important role to AP activation in the pathogenesis of
epidermolysis bullosa acquisita (38). It was hypothesized that the
AP serves as an amplification loop upon CP or LP activation,
which are likely to compensate for each other. Notably, a role
for ficolins in complement activation and amplification loop
initiation cannot be fully excluded. Alternatively, AP might be
activated upon binding of autoantibodies against complement
regulator proteins.
More downstream, epidermolysis bullosa acquisita is likely
to be C5aR1-dependent, since C5aR1-deficient animals were
protected against development of epidermolysis bullosa acquisita
(37, 39). Moreover, animals pretreated with anti-C5aR1 antibody
developed a less severe blistering phenotype compared to
controls. No protection was found in C6-deficient animals,
excluding a major role for MAC formation in epidermolysis
bullosa acquisita. In summary, these experimental models
demonstrate involvement of CP- and AP-activation and C5a-
C5aR1-axis activation in the development of epidermolysis
bullosa acquisita.
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LINEAR IGA DISEASE
Linear IgA disease (LAD) is defined as a rare group of
subepidermal bullous diseases where IgA-autoantibodies target
the epidermal BMZ. Patients present with pruritic blisters
consisting of grouped vesicles on erythematous bases. The
most common antigen targets are LAD-1 and LABD97, which
are cleavage products of the extracellular domain of BP180.
Histologically, a subepidermal blister is seen with neutrophils
aligned along the dermal-epidermal junction or filling up the
dermal papillae. DIF shows linear deposition of IgA along
the BMZ.
The pathogenesis of LAD can be complement-dependent and
-independent. Recent studies have shown that crosslinking of
FcαRI on neutrophils by IgA-immune-complexes can directly
initiate immune responses and activation and migration of
neutrophils in LAD, independent of complement (40, 41).
Although IgA is a weak activator of complement in comparison
to IgM and IgG, in practice, deposition of C3 can be found in
LAD up to 30% (42, 43). Since IgA does not have a C1q-binding
site, it cannot activate the CP, but it can activate both the AP
and LP (44, 45). It is known from patients with IgA-vasculitis
and IgA-nephropathy that particularly the LP can be activated
upon binding of MBL and ficolins to IgA deposits in vessel walls
or glomeruli (45–47) Whether AP and LP are also involved in
the pathogenesis of LAD remains to be investigated. Although
complement is deposited in LAD, further research is needed to
determine the contribution of complement to the pathogenesis
of LAD.
DERMATITIS HERPETIFORMIS
Dermatitis herpetiformis (DH) is a rare cutaneous manifestation
of celiac disease that mostly manifests in adults. Patients with
DH present with highly pruritic papulovesicular eruptions on
various extensor surfaces. Celiac disease is characterized by IgA-
autoantibodies against tissue transglutaminase while DH also
shows antibodies against epidermal transglutaminase. The tissue
transglutaminase modifies a fraction of gluten, gliadin, to an
antigen which binds to an HLA-DQ2 or HLA-DQ8 molecule,
provoking an autoimmune reaction. The IgA autoantibodies
against epidermal transglutaminase are deposited as granular
immune-complexes in the dermis. Histology shows characteristic
micro-abscesses and granular IgA-deposits in papillary dermis
while C3-deposition can be found in up to 89% (48). Seah et al.
suggested that complement is activated via the AP since no
deposits of C1q were found in DH biopsies (48). Although IgA
does not activate the CP of complement, the mere absence of
C1q does not exclude CP activation since C1q has a relatively low
half-life in tissue. For definitive proof of AP activation, Provost
et al. demonstrated specific deposition of FB and properdin as
markers of AP activation in DH (49). Also, the role of the LP
cannot be ruled out and remains to be investigated. In addition
to granular C3-deposition in DH, Preisz and colleagues also
found vascular immune precipitates and C3-deposition in DH
that strongly co-localized with epidermal transglutaminase (50).
As previously discussed in the segment about LAD, the immune
reaction in DH can also be complement-independent due to
crosslinking of FcαRI with IgA-immune-complexes. However,
since the percentage of C3-deposition is higher in DH, this likely
to occur less often than in LAD.
PEMPHIGUS
Pemphigus includes a group of rare chronic blistering diseases
characterized by IgG-autoantibodies directed against a variety
of desmosomal transmembrane glycoproteins. Patients with
pemphigus vulgaris typically present with lesions of the oral
mucosa followed by skin-involvement and autoantibodies are
directed against epithelial adhesion protein desmoglein 3 and/or
desmoglein 1. In pemphigus foliaceus the lesions are localized
on the skin, without involvement of the mucous membranes,
and autoantibodies are directed against desmoglein 1. DIF
studies demonstrate intercellular deposition of IgG and C3c,
which suggests involvement of complement activation in the
pathogenesis of pemphigus. Furthermore, components of all
complement activation pathways can be found in the intercellular
substance (ICS) including C1q, properdin, C3, C5, MBL, ficolins,
and the MAC (51–53). Nevertheless, animal models have shown
that blister formation in pemphigus can be independent of
complement activation. In an experimental passive IgG-transfer
mouse model, pathogenic patient pemphigus vulgaris IgG and
F(ab′)2 were equally pathogenic, while the latter failed to induce
complement C3-deposition. In the same model using only
pemphigus vulgaris IgG, C5-deficient, or cobra venom factor
pretreated neonatal mice also developed pemphigus blisters (54).
Although this data indicates a minor role for complement in
pemphigus, the results should be interpreted with caution. In
contrast to high-dose pemphigus vulgaris IgG, complement-
depleted animals transferred with low-dose pemphigus vulgaris
IgG showed more limited and delayed onset of disease. Thus,
complement activation might not be essential, but potentiates
the pathogenicity of autoantibodies in experimental pemphigus.
Whether complement plays a role in the initiation and or
propagation of pemphigus in humans remains to be investigated.
TARGETING THE COMPLEMENT SYSTEM
IN AUTOIMMUNE
BULLOUS DERMATOSES
The greatest challenge in targeting complement activation,
is to find the optimal balance between sufficient blocking
and preservation of complement activity. Complete blocking
of complement activation is undesirable since this is highly
associated with infections. At this moment, no complement
targeting drugs have been approved for clinical use in AIBD.
Recently, Kasprick et al. found that treatment with a mouse
monoclonal anti-C1s antibody (TNT003) significantly reduced
C3c-deposition and production of C4a and C5a, as well as
neutrophil chemoattraction in an ex-vivo human skin cryosection
assay (55). These results show that early inhibition of the CP can
prevent IgG-induced complement activation in-vitro. Although
the in vivo effect on inflammation or blistering is unknown,
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this data provides rationale to test Sutimlimab, a humanized
monoclonal of TNT003, which was shown to be safe and well-
tolerated in humans (56, 57). Selective CP inhibition without
interfering in AP and LP opens new and safe opportunities
for interventions in BP, thereby leaving important arms of the
CS intact.
Other possible ways to inhibit the CS includes the inhibition
of the C5a-C5aR axis. The anti-C5 monoclonal antibody
Eculizumab binds to C5, thereby preventing cleavage into its
active components, but has been associated with a thousand-
fold increased risk of meningococcal disease (58). Coversin (a
recombinant small protein) is another anti-C5 drug that is
currently in phase IIA of clinical trials in BP-patients. In addition
of binding C5, it also inhibits leukotriene B4, another powerful
inflammatory mediator (https://adisinsight.springer.com/trials/
700284185). Although C5-blocking drugs are interesting, it will
also interfere with C5a-C5aR2-axis activation, which has recently
shown protective effects in BP (17). Therefore, inhibition of
C5a-C5aR1 axis might be more interesting, leaving C5a-C5aR2
interaction intact. Avacopan is an oral small molecule C5aR1-
inhibitor and has shown promising results in clinical trials by
having a long half-life and showing limited side effects (59).
Further studies are needed to investigate the mechanisms of
complement activation in humans which provides a basis for
developing more specific therapeutic approaches targeting key
complement component, pathways and pathogenic events.
CONCLUSION
It has been shown through various experimental and clinical
studies that the CS plays a role in several AIBD. In animals
models using complement-deficient mice, different complement
pathways are involved in the pathogenesis of different AIBD.
Although recent clinical studies in BP found association
of complement with disease activity, it still remains to be
investigated how important the CS is in the pathogenesis of other
AIBD. In the last few years multiple drugs targeting specific
parts of the CS are in clinical development and some of these
have shown promising results in preclinical studies. Selective
neutralization of pathway-specific or terminal cascade specific
components is promising, since this leaves most other parts of
the CS intact. As with all new drugs, the ratio of risk to benefit for
the patient must be assessed in future clinical trials.
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